Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    6%
    Check dated 2025-10-05T17:27:17.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Upgrade version from v3.0.2 to v3.1.0; no other content changes are specified.
    Difference
    0.1%
    Check dated 2025-09-28T10:14:32.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.
    Difference
    0.4%
    Check dated 2025-09-14T00:22:10.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.4%
    Check dated 2025-09-06T21:22:20.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, while several key medical terms and topics related to cancer treatment have been removed.
    Difference
    5%
    Check dated 2025-08-30T15:59:35.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.11 to v2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T12:55:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.